Zhicai Wu

USPTO Granted Patents = 36 (Patent Applications = 12)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 26 (Patent Applications = 22)

Average Co-Inventor Count = 8.5

ph-index = 7

Forward Citations = 147(Granted Patents)

Location History:

Quakertown, PA (US) (2006 - 2011)
Hillsdale, NJ (US) (2011)
Kenilworth, NJ (US) (2018 - 2020)
Montvale, NJ (US) (2014 - 2021)

Company Filing History:

27 out of 2,405

Merck Sharp + Dohme Corp.

Merck Shapr & Dohme Corp.

patent

4. 1 out of 832,680

Other

patents

Years Active: 2006-2025

Loading Chart...

36 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

2. 12440496 - Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes (2025-10-14),

3. 11014920 - Factor XIIa inhibitors (2021-05-25),

4. 10875851 - Factor XIIa inhibitors (2020-12-29),

5. 10800827 - Insulin receptor partial agonists (2020-10-13),

6. 10689430 - Insulin receptor partial agonists (2020-06-23),

7. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),

8. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

9. 10183981 - Insulin receptor partial agonists (2019-01-22),

10. 10017556 - Insulin receptor partial agonists (2018-07-10),

11. 9868733 - Azabenzimidazole tetrahydrofuran derivatives (2018-01-16),

12. 9751881 - Inhibitors of the renal outer medullary potassium channel (2017-09-05),

13. 9556193 - Benzimidazole hexahydrofuro[3,2-b]furan derivatives (2017-01-31),

14. 9540364 - Benzimidazole tetrahydrofuran derivatives (2017-01-10),

15. 9527839 - Benzimidazole tetrahydropyran derivatives (2016-12-27),

Title: Innovator Spotlight - Zhicai Wu: Pioneering Factor XIIa Inhibitors

Introduction:

Meet Zhicai Wu, a prolific inventor based in Montvale, NJ, with an impressive portfolio of 34 patents. His groundbreaking work in developing Factor XIIa inhibitors is revolutionizing the field of thrombosis and coagulation disorders. Let's delve into his latest patents, career highlights, and notable collaborations.

Latest Patents:

Zhicai Wu's latest patents focus on Factor XIIa inhibitors, compounds designed to treat and prevent thromboses, embolisms, hypercoagulability, and fibrotic changes. These compounds, represented by Formula I, demonstrate exceptional selectivity in inhibiting Factor XIIa, offering promising avenues for novel therapeutic interventions in clotting disorders.

Career Highlights:

With a remarkable career spanning multiple prestigious organizations, Zhicai Wu has contributed significantly to the pharmaceutical industry. Notably, he has lent his expertise to renowned companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His innovative approach to drug development underscores his commitment to advancing healthcare and improving patient outcomes.

Collaborations:

Throughout his career, Zhicai Wu has collaborated closely with accomplished professionals in the field, including colleagues such as Danqing D Feng and Ahmet Kekec. Together, they have synergized their talents and insights to drive forward cutting-edge research initiatives, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Zhicai Wu stands as a trailblazing inventor at the forefront of pharmaceutical innovation, particularly in the realm of Factor XIIa inhibitors. His relentless pursuit of scientific advancement, coupled with his collaborations and industry expertise, showcases his unwavering dedication to transforming healthcare landscapes. Zhicai Wu's pioneering work serves as a testament to the transformative power of inventions in shaping a healthier future for all.

This text is generated by artificial intelligence and may not be accurate.